GLP-1 Receptor Agonists for Neurological Disease

Semaglutide (Ozempic) was designed for diabetes but Danish registry data from 1.4 million patients shows 40 to 70 percent lower rates of Alzheimer and Parkinson disease diagnosis in users. Phase 3 trials for Alzheimer prevention are underway. If confirmed, GLP-1 agonists would simultaneously treat obesity, metabolic disease, and neurodegeneration in a single medication.